InMed Pharmaceuticals (FRA:MWG) Beta: 2.0871 (As of Jun. 25, 2026)


FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
29 GF Score
Price €1.27
GF Value €0.76
! 3 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Beta?

InMed Pharmaceuticals FRA:MWG +0.79% 29 Beta is 2.0871 as of Jun. 25, 2026. GuruFocus rates FRA:MWG with a GF Score™ of 29/100 and a GF Value™ of €0.76. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), InMed Pharmaceuticals's Beta is 2.0871.


InMed Pharmaceuticals  (FRA:MWG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


InMed Pharmaceuticals Beta Related Terms


InMed Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Beta Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.62 0.80 0.00 -0.53 -0.92

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.92 -0.90 -0.26 -0.04

FRA:MWG vs GELS, LVRLF, BUDZ: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Beta falls into.


FRA:MWG
29GF Score
InMed Pharmaceuticals Inc FRA:MWG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.0871 mean?
InMed Pharmaceuticals (FRA:MWG) has a Beta of 2.0871 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Beta too high?
InMed Pharmaceuticals' current Beta is 2.0871. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Beta compare to GELS and LVRLF?
InMed Pharmaceuticals' Beta of 2.0871 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Beta is 2.0871. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (FRA:MWG) has a current Beta of 2.0871. The stock's GF Value™ is €0.76, compared to a current price of €1.27 — trading 67.1% above its estimated fair value. The current Beta is 2.0871. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current Beta is 2.0871 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.27 is trading 67.1% above its estimated GF Value™ of €0.76.

Key valuation signals for FRA:MWG:

  • Beta: 2.0871
  • GF Value™: €0.76 vs. price of €1.27 (67.1% above fair value)
  • GF Score™: 29/100 with 3 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for FRA:MWG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.27
Price
€0.76
GF Value